SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$221M
Q1 2020
Positions
51
Filings on Record
24
2019–present window
Filed
May 15, 2020
original filing

Summary

Endurant Capital Management LP reported $221M in U.S.-listed holdings across 51 positions for Q1 2020.

Its largest position, SNY, represents 8.1% of the portfolio.

Compared with Q4 2019, the fund opened 20 new positions and exited 22.

Portfolio Metrics

Turnover
+36.7%
vs prior filed quarter
Top-10 Concentration
+60.2%
share of reported value
Largest Position
+8.1%
Sanofi
New / Exited
20 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 74.9%Other: 10.2%ADR: 10.1%US DOMESTIC: 4.9%
  • Common Stock · 74.9% · $165M
  • Other · 10.2% · $22M
  • ADR · 10.1% · $22M
  • US DOMESTIC · 4.9% · $11M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SNYSANOFINEW+410.0K410.0K+$18M$18M
PFEPFIZER INCNEW+510.1K510.1K+$17M$17M
HO1HOLOGIC INCNEW+473.7K473.7K+$17M$17M
JNJJOHNSON & JOHNSONNEW+48.5K48.5K+$6M$6M
AVTRAVANTOR INCNEW+249.4K249.4K+$3M$3M
AMGNAMGEN INCNEW+13.2K13.2K+$3M$3M
BMRNBIOMARIN PHARMACEUTICAL INCNEW+28.6K28.6K+$2M$2M
TAKEDA PHARMACEUTICAL CO LTDNEW+156.1K156.1K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SNYSANOFIhistory →SPONSORED ADR8.12%$18M410.0K
2PFEPFIZER INChistory →COM7.55%$17M510.1K
3HO1HOLOGIC INChistory →COM7.53%$17M473.7K
4SIBNSI BONE INChistory →COM7.16%$16M1.32M
5OXFORD IMMUNOTEC GLOBAL PLCORD SHS7.12%$16M1.70M
6CICIGNA CORP NEWhistory →COM5.74%$13M71.4K
7ELVANTHEM INChistory →COM4.46%$10M43.4K
8ZBHZIMMER BIOMET HOLDINGS INChistory →COM4.31%$10M94.1K
9EVOLENT HEALTH INCNOTE 2.000%12/04.20%$9M11.10M
10ZTSZOETIS INChistory →CL A4.01%$9M75.2K
11BMYBRISTOL-MYERS SQUIBB COhistory →COM3.46%$8M136.9K
12BDXBECTON DICKINSON & COhistory →COM3.23%$7M31.0K
13JNJJOHNSON & JOHNSONhistory →COM2.88%$6M48.5K
14MCKMCKESSON CORPhistory →COM2.23%$5M36.4K
15RCMEURR1 RCM INChistory →COM2.00%$4M484.8K
16EHCENCOMPASS HEALTH CORPhistory →COM1.61%$4M55.6K
17AHCOADAPTHEALTH CORPhistory →COM CL A1.60%$4M220.9K
18LABORATORY CORP AMER HLDGSCOM NEW1.51%$3M26.3K
19PRAHPRA HEALTH SCIENCES INChistory →COM1.46%$3M38.8K
20AVTRAVANTOR INChistory →COM1.41%$3M249.4K
21PROTHENA CORP PLCSHS1.24%$3M255.9K
22ACRSACLARIS THERAPEUTICS INChistory →COM1.23%$3M2.62M
23AMGNAMGEN INChistory →COM1.21%$3M13.2K
24HRCHILL ROM HLDGS INChistory →COM1.20%$3M26.2K
25BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.10%$2M28.6K
26TAKEDA PHARMACEUTICAL CO LTDSPONSORED ADS1.07%$2M156.1K
27CNCCENTENE CORP DELhistory →COM1.03%$2M38.2K
28TRLDAVITA INCCOM0.94%$2M27.2K
29XRAYDENTSPLY SIRONA INCCOM0.93%$2M52.6K
30TREURTRILLIUM THERAPEUTICS INCCOM NEW0.87%$2M477.7K
31CHARLES RIV LABS INTL INCCOM0.75%$2M13.1K
32SENSEONICS HLDGS INCNOTE 5.250% 2/00.67%$1M1.50M
33GW PHARMACEUTICALS PLCADS0.67%$1M16.9K
34ZGNXEURZOGENIX INCCOM NEW0.66%$1M58.8K
35IM8NINSMED INCCOM PAR $.010.54%$1M74.4K
36ATRCATRICURE INCCOM0.51%$1M33.5K
37FATEFATE THERAPEUTICS INCCOM0.41%$905,00040.7K
38IQVIQVIA HLDGS INCCOM0.41%$899,0008.3K
39AXSMAXSOME THERAPEUTICS INCCOM0.33%$728,00012.4K
40AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.32%$696,00087.7K
41SELECTA BIOSCIENCES INCCOM0.28%$615,000255.3K
42IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.27%$605,00020.2K
43FLBFLUIDIGM CORP DELCOM0.27%$590,000232.3K
44PRNBPRINCIPIA BIOPHARMA INCCOM0.24%$530,0008.9K
45MGNXMACROGENICS INCCOM0.23%$510,00087.7K
46HCAHCA HEALTHCARE INCCOM0.23%$509,0005.7K
47GNCAQGENOCEA BIOSCIENCES INCCOM NEW0.21%$455,000264.3K
48ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.20%$435,000159.8K
49OVIDOVID THERAPEUTICS INCCOM0.16%$347,000116.3K
50PETSPETMED EXPRESS INCCOM0.13%$287,00010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.